ABOS News and Press, Acumen Pharmaceuticals Inc. From 07/17/23

2023-07-17 10:00:46 ET Shares of Acumen Pharmaceuticals ( NASDAQ: ABOS ) rallied more than 60% in early trading Monday in the wake of the release of positive data from a Phase 1 clinical trial for its Alzheimer's disease drug candidate ACU193. Acumen shares opened at a $6.11, re...

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s dis...

Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody Rapid, dose-related, statistically significant (p=0.01) amyloid plaque reduction ob...

2023-07-13 08:03:58 ET Summary Acumen will present Phase 1 topline data on its Alzheimer’s therapeutic candidate, ACU193, at the annual Alzheimer’s Association International Conference. ACU193 is an anti-beta amyloid with a unique binding profile. Results of the ...

2023-07-11 13:19:00 ET Gainers: Eloxx Pharmaceuticals ( ELOX ) +112% . CytoMed Therapeutics Limited ( GDTC ) +102% . Biodexa Pharmaceuticals ( BDRX ) +92% . SOS Limited ( SOS ) +39% . Freeline Therapeutics Holdings ( FRLN ) +33% ...

2023-07-11 10:06:43 ET Gainers: CytoMed Therapeutics ( GDTC ) +128% . Eloxx Pharmaceuticals ( ELOX ) +29% . UpHealth ( UPH ) +13% . Virios Therapeutics ( VIRI ) +13% . Acumen Pharmaceuticals ( ABOS ) +9% . Losers: Jou...

2023-07-11 08:13:18 ET CytoMed Therapeutics ( NASDAQ: GDTC ) +177% . Dragonfly Energy ( DFLI ) +19% Partners with World’s Largest Teardrop Manufacturer to Provide Full Lithium Power Systems. Acumen Pharmaceuticals ( ABOS ) +17% . Eloxx Pharma...

2023-07-07 10:20:40 ET Summary Esai and Biogen's Alzheimer's Disease therapeutic, Leqembi, received full FDA approval on July 6th. Full approval likely means at least $100s millions/annual revenue since Medicare will reimbursement most of the patient cost for Leqembi. With the...

SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its Board of...

Topline results for ACU193, the first clinical stage amyloid beta oligomer (A βO)-directed antibody, to provide deeper insight into candidate’s therapeutic potential for the treatment of early Alzheimer’s disease Phase 1 INTERCEPT-AD data investigating safety, pha...